Clinical Gastroenterology and Hepatology
Volume 4, Issue 8 , Pages 1048-1052 , August 2006

Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement

  • Glen Lutchman

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Kittichai Promrat

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • David E. Kleiner

      Affiliations

    • Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland
    • ,
  • Theo Heller

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Marc G. Ghany

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Jack A. Yanovski

      Affiliations

    • Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
    • ,
  • T. Jake Liang

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Jay H. Hoofnagle

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationAddress requests for reprints to: Dr. Jay H. Hoofnagle, Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 31, Room 9A27, Bethesda, Maryland 20892; fax:(301)480-7926.

References 

  1. Ruhl CE , Everhart JE . Epidemiology of nonalcoholic fatty liver . Clin Liver Dis . 2004;8:501–519 vii
  2. McCullough AJ . The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease . Clin Liver Dis . 2004;8:521–533 viii
  3. Ludwig J , Viggiano TR , McGill DB , et al.   Nonalcoholic steatohepatitis (Mayo Clinic experiences with a hitherto-unnamed disease) . Mayo Clin Proc . 1980;55:434–438
  4. Kleiner DE , Brunt EM , Van Natta M , et al.   Design and validation of a histological scoring system for nonalcoholic fatty liver disease . Hepatology . 2005;41:1313–1321
  5. Charlton M , Kasparova P , Weston S , et al.   Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease . Liver Transpl . 2001;7:608–614
  6. Bacon BR , Farahvash MJ , Janney CG , et al.   Nonalcoholic steatohepatitis (an expanded clinical entity) . Gastroenterology . 1994;107:1103–1109
  7. Marchesini G , Bugianesi E , Forlani G , et al.   Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome . Hepatology . 2003;37:917–923
  8. Yki-Jarvinen H . Thiazolidinediones . N Engl J Med . 2004;351:1106–1118
  9. Caldwell SH , Hespenheide EE , Redick JA , et al.   A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis . Am J Gastroenterol . 2001;96:519–525
  10. Neuschwander-Tetri BA , Brunt EM , Wehmeier KR , et al.   Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPARγ ligand rosiglitazone . Hepatology . 2003;38:1008–1017
  11. Sanyal AJ , Mofrad PS , Contos MJ , et al.   A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis . Clin Gastroenterol Hepatol . 2004;2:1107–1115
  12. Promrat K , Lutchman G , Uwaifo GI , et al.   A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis . Hepatology . 2004;39:188–196
  13. Rajala MW , Scherer PE . Minireview. The adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis . Endocrinology . 2003;144:3765–3773
  14. Friedman JM . The function of leptin in nutrition, weight, and physiology . Nutr Rev . 2002;60:S1–S14
  15. Scherer PE , Williams S , Fogliano M , et al.   A novel serum protein similar to C1q, produced exclusively in adipocytes . J Biol Chem . 1995;270:26746–26749
  16. Xu A , Wang Y , Keshaw H , et al.   The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice . J Clin Invest . 2003;112:91–100
  17. You M , Considine RV , Leone TC , et al.   Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice . Hepatology . 2005;42:568–577
  18. Kamada Y , Tamura S , Kiso S , et al.   Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin . Gastroenterology . 2003;125:1796–1807
  19. Ding X , Saxena NK , Lin S , et al.   The roles of leptin and adiponectin (a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology) . Am J Pathol . 2005;166:1655–1669
  20. Javor ED , Ghany MG , Cochran EK , et al.   Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy . Hepatology . 2005;41:753–760
  21. Diehl AM . Lessons from animal models of NASH . Hepatol Res . 2005;33:138–144
  22. Vuppalanchi R , Marri S , Kolwankar D , et al.   Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study . J Clin Gastroenterol . 2005;39:237–242
  23. Musso G , Gambino R , Durazzo M , et al.   Adipokines in NASH (postprandial lipid metabolism as a link between adiponectin and liver disease) . Hepatology . 2005;42:1175–1183
  24. Li Z , Yang S , Lin H , et al.   Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease . Hepatology . 2003;37:343–350
  25. Park HS , Park JY , Yu R . Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α, and IL-6 . Diabetes Res Clin Pract . 2005;69:29–35
  26. Afford SC , Fisher NC , Neil DA , et al.   Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis . J Pathol . 1998;186:82–89
  27. Saxena NK , Ikeda K , Rockey DC , et al.   Leptin in hepatic fibrosis (evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice) . Hepatology . 2002;35:762–771
  28. Angulo P , Alba LM , Petrovic LM , et al.   Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease . J Hepatol . 2004;41:943–949
  29. Shand BI , Scott RS , Elder PA , et al.   Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance . Diabetes Obes Metab . 2003;5:349–353
  30. Miyazaki Y , Mahankali A , Wajcberg E , et al.   Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients . J Clin Endocrinol Metab . 2004;89:4312–4319

 Supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Dr Yanovski is a Commissioned Officer in the US Public Health Service.

PII: S1542-3565(06)00470-8

doi: 10.1016/j.cgh.2006.05.005

Clinical Gastroenterology and Hepatology
Volume 4, Issue 8 , Pages 1048-1052 , August 2006